Intellia Therapeutics has reported that its investigational in vivo CRISPR therapy, lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002), met its primary endpoint in the Phase 3 HAELO trial for hereditary angioedema (HAE), reducing investigator-confirmed attacks by 87% compared with placebo. The results were presented in a late-breaking session at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congress and have been published in the New England Journal of Medicine.
What the trial actually measured
HAELO (registered at ClinicalTrials.gov as NCT06634420) is a randomized, double-blind, placebo-controlled Phase 3 study in adults and adolescents aged 16 and older with Type I or Type II hereditary angioedema, a rare genetic condition that causes recurrent, potentially life-threatening swelling attacks. Participants were randomized 2:1 to a single dose of lonvo-z or placebo, with an optional blinded crossover to active treatment at week 28. The primary outcome measure was the reduction in investigator-confirmed HAE attack rate between weeks five and 28 after dosing — the 87% figure is a between-arm reduction on that specific measure, not a claim that the drug eliminates attacks in every patient. A secondary endpoint found 62% of lonvo-z recipients were completely attack-free over six months, compared with 11% of the placebo group.
How the therapy works
Lonvo-z is an in vivo CRISPR-based gene-editing therapy: rather than editing cells outside the body and reinfusing them, it is administered as a single intravenous dose designed to directly inactivate the KLKB1 gene, which encodes prekallikrein, in the patient’s liver cells. Prekallikrein sits upstream of the bradykinin pathway that drives HAE swelling attacks, so durably reducing its production is the mechanism behind the sustained attack-rate reduction. Because the edit is intended to be permanent, the therapy is being developed as a potential one-time treatment rather than the chronic, recurring-dose prophylactic therapies that are the current standard of care.
A trial designed with a specific safety question in mind
Intellia has flagged this dataset’s safety and tolerability profile as “favourable,” a result that matters more than it might for an ordinary readout: the company’s other in vivo CRISPR program, nexiguran ziclumeran (for transthyretin amyloidosis), was placed on an FDA clinical hold over liver toxicity concerns in a separate trial. HAELO’s trial design and safety monitoring were built around exactly that kind of hepatic risk, since the therapy targets liver cells directly — a reminder that in vivo gene-editing trials carry organ-specific safety questions that trial protocols have to be built to catch, not just efficacy questions.
Where the therapy stands regulatorily
Lonvo-z is still investigational and not yet approved by the FDA or any other regulator. Intellia has begun a rolling Biologics License Application submission with the FDA following the Phase 3 readout, with a potential U.S. approval and launch targeted for the first half of 2027. Until that review concludes, the correct characterization of this result is a positive, statistically significant Phase 3 efficacy and safety readout on a still-investigational one-time gene-editing therapy — not an approved cure.
Sources: Intellia Therapeutics HAELO Phase 3 trial results, presented at EAACI 2026 Congress; published in the New England Journal of Medicine (DOI: 10.1056/NEJMoa2600931); ClinicalTrials.gov NCT06634420.
